摘要
目的比较以多西他赛为基础的DCF三药联合方案与DF/DX两药联合方案一线治疗晚期胃癌的临床疗效和毒副作用。方法收集我科104例一线化疗以多西他赛为基础的晚期胃癌患者,其中DCF三药联合方案组共53例、DF/DX两药联合组共51例,所有患者至少接受以上方案2个周期,评价疗效。结果两组有效率、疾病控制率、中位总生存时间及毒副作用发生率比较,差异均无统计学意义(P>0.05);DCF三药联合组中位无疾病进展时间(PFS)高于DF/DX两药联合组,差异有统计学意义(P=0.016)。结论 DCF三药联合方案治疗晚期胃癌的PFS较长,但对于总生存期并无明显延长,且毒副作用较大,年龄不高、化疗耐受好的患者可考虑DCF三药联合,DF/DX两药联合方案也可以作为晚期胃癌的有效化疗方案选择。
Objective To compare the efficacy and side effect of DCF three - drug combined and DF / DX two - drug combined with docetaxel - based in the first - line treatment of advanced gastric cancer. Methods 104 patients with ad- vanced gastric cancer were chosen with first - line chemotherapy with docetaxel. A total of 53 cases in the DCF three drug combi- nation group, a total of 51 cases in the DF/DX two drug combination group, all patients were accepted the above plan at least two cycles, the curative effect were evaluated. Results The efficiency, disease control rate, median overall survival time and the incidence of side effects in two groups were compared, the difference was not statistically significant （ P 〉 0.05 ） ; The median time to progression （PFS） DCF three - drug combination group was higher than that of DF/DX two - drug combination group （ P = O. 016）. Conclusion DCF three - drug combination PFS longer, but do not significantly prolong overall survival and toxic side effects, age is not high tolerance to chemotherapy may be considered in patients with good DCF three - drug combination, DF/DX two - drug combination scheme can also be used as effective chemotherapy regimen for advanced gastric cancer selection.
出处
《实用心脑肺血管病杂志》
2013年第10期38-40,共3页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词
胃肿瘤
晚期
多西他赛
治疗结果
Stomach neoplasms
Advanced
Docetaxel
Treatment outcome
